Loading...
menu
Search
AI Trading Bot
Features
Markets
News
Resources
Pricing
Get Started
Home
ETF
AXSM
AXSM
-
Add to Watchlist
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
Overview
Technical
News
AXSM News
Summit Therapeutics Faces FDA Review Risk for Ivonescimab
5d ago
Fool
Summit Therapeutics Faces FDA Approval Risk for Ivonescimab
5d ago
NASDAQ.COM
Superstring Capital Acquires Position in Axsome Therapeutics
Mar 18 2026
Fool
Investigation into Atkore and Others by Johnson Fistel
Mar 12 2026
Globenewswire
Undervalued Investment Opportunities: Axsome and Madrigal
Mar 10 2026
Fool
Axsome and Madrigal's Market Potential
Mar 10 2026
NASDAQ.COM
Axsome Therapeutics CEO Sells Shares Amid Expiring Options
Mar 09 2026
Fool
Helus Pharma's Psychedelic Drug Achieves Phase 3 Success
Feb 26 2026
PRnewswire
Helus Pharma Achieves Breakthrough in Depression Treatment
Feb 26 2026
Newsfilter
UBS Increases Target Price for AXSOME THERAPEUTICS INC to $251, Up from $248
Feb 24 2026
moomoo
Wall Street Analysts Adjust Ratings on Key Stocks
Feb 24 2026
Benzinga
Axsome Reports Q4 Revenue Exceeding Expectations
Feb 23 2026
stocktwits
Axsome Therapeutics Q4 2025 Earnings Call Highlights
Feb 23 2026
seekingalpha
Axsome (AXSM) Q4 2025 Earnings Call Transcript
Feb 23 2026
NASDAQ.COM
Axsome Therapeutics Q4 Earnings Exceed Expectations
Feb 23 2026
seekingalpha
Wall Street Focus This Week: Nvidia Earnings Report
Feb 22 2026
CNBC
Show More News
